Mnk kinase homologous proteins involved in the regulation of energy homeostasis and organelle metabolism
This invention relates to the use of nucleic acid sequences of the MAP kinase-interacting kinase (Mnk) gene family and amino acid sequences encoded thereby, and to using these sequences or effectors of Mnk nucleic acids or polypeptides, particularly Mnk kinase inhibitors and activators, in the diagnosis and treatment of diseases and disorders related to body-weight regulation and thermogenesis. One aspect of the disclosure encompasses methods of identifying an animal or human having an elevated probability of having or developing a pancreatic malfunction, the method comprising: (a) obtaining a biological sample from an animal or human subject; and (b) determining from the biological sample whether the subject has a genetic variant of an Mnk2 and/or Mnk1 gene or a homolog thereof, or an expression product of said Mnk2 and/or Mnk1 gene or homolog thereof, wherein said genetic variant is associated with an elevated probability of having or developing a pancreatic malfunction.
1. A method of screening for a candidate inhibitor of a pancreatic malfunction that decreases the kinase activity of Mitogen Activating Protein Kinase Interacting Kinases Mnk2a or Mnk2b, wherein said kinase activity is associated with type 2 diabetes, said method comprising the steps of:
(a) identifying an inhibitor of the kinase activity of Mnk2a or Mnk2b by:
(i) determining a first level of kinase activity of Mnk2a or Mnk2b in the absence of a candidate Mnk2 inhibitor;
(ii) determining a second level of kinase activity of Mnk2a or Mnk2b in the presence of the Mnk2 candidate inhibitor;
(iii) comparing the first and the second levels of the kinase activity of the Mnk2a or Mnk2b, wherein if the second level of kinase activity is less than the first level then the candidate inhibitor is identified as an Mnk2 inhibitor; and
(b) determining if the Mnk2 inhibitor identified from step (iii) increases insulin-stimulated glucose transport and lipid synthesis during adipogenesis of preadipocyte cells, thereby identifying the Mnk2 inhibitor as a candidate for screening as an inhibitor of type 2 diabetes.
2. The method of claim 1 , wherein the candidate inhibitor is selected from the group consisting of: a peptide and a small organic compound having a molecular weight of more than 50 Da and less than about 2500 Da.
3. The method of claim 1 , wherein a known Mnk inhibitor is used as a control for the candidate inhibitor which decreases the kinase activity of Mnk2a or Mnk2b.